[1] FISHER RA.Statistical tests[J]. Nature, 1935, 136(3438): 474. [2] BÉGAUD B. Dictionnary of pharmacoepidemiology[M]. Chichester, UK: John Wiley & Sons Ltd, 2000. [3] GRIMES DA, SCHULZ KF.Bias and causal associations in observational research[J]. Lancet (London, England), 2002, 359(9302): 248-252. [4] MA H, LI X, SUN D, et al.Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank[J]. BMJ, 2019, 365: l1628. [5] WASSERSTEIN RL, LAZAR NA.The ASA statement on p-values: context, process, and purpose[J]. The American Statistician, 2016, 70(2): 129-133. [6] ALTMAN DG, BLAND JM.Statistics notes: Absence of evidence is not evidence of absence[J]. BMJ, 1995, 311(7003): 485. [7] SIMMONS JPNL, SIMONSOHN U.False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant[J]. Psychological Science, 2011, 22(11): 1359-1366. [8] MOTULSKY HJ.Common misconceptions about data analysis and statistics[J]. The Journal of Pharmacology and Experimental Therapeutics, 2014, 351(1): 200-205. [9] LI G, KAMEL M, JIN Y, et al.Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey[J]. Journal of Multidisciplinary Healthcare, 2018, 11: 39-47. [10] CHAN AW.Bias, spin, and misreporting: time for full access to trial protocols and results[J]. PLoS Medicine, 2008, 5(11): e230. [11] BOUTRON I, DUTTON S, RAVAUD P, et al.Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes[J]. JAMA, 2010, 303(20): 2058-2064. [12] WAKEFIELD AJ, MURCH SH, ANTHONY A,et al.Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children[J]. Lancet (London, England), 1998, 351(9103): 637-641. [13] The Editors of The Lancet. Retracted-ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children[J]. Lancet (London, England), 2010, 375(9713): 445. [14] LI G, WALTER S, THABANE L.Shifting the focus away from binary thinking of statistical significance and towards education for key stakeholders: revisiting the debate on whether it's time to de-emphasize or get rid of statistical significance[J]. J Clin Epidemiol, 2021, 137: 104-112. [15] HURLBERT SH, LEVINE RA, UTTS J.Coup de grâce for a tough old bull:“Statistically significant”expires[J]. The American Statistician, 2019, 73(sup1): 352-357. [16] WASSERSTEIN RL, SCHIRM AL, LAZAR NA.Moving to a world beyond“P< 0.05”[J]. The American Statistician, 2019, 73(sup1): 1-19. [17] AMRHEIN V, GREENLAND S, MCSHANE B.Scientists rise up against statistical significance[J]. Nature, 2019, 567(7748): 305-307. [18] BENJAMIN DJ, BERGER JO, JOHANNESSON M, et al.Redefine statistical significance[J]. Nature Human Behaviour, 2018, 2(1): 6-10. [19] VAN CALSTER B, STEYERBERG EW, COLLINS GS, et al.Consequences of relying on statistical significance: some illustra-tions[J]. European Journal of Clinical Investigation, 2018, 48(5): e12912. [20] STEYERBERG EW, VAN CALSTER B.Redefining significance and reproducibility for medical research: a plea for higher P-value thresholds for diagnostic and prognostic models[J]. European Journal of Clinical Investigation, 2020, 50(5): e13229. [21] IOANNIDIS JP.Retiring statistical significance would give bias a free pass[J]. Nature, 2019, 567(7749): 461-462. [22] FRICKER JR RD, BURKE K, HAN X, et al.Assessing the statistical analyses used in basic and applied social psychology after their P-value ban[J]. The American Statistician, 2019, 73(sup1): 374-384. |